PGLa TFA

Cat. No.:	HY-P0274A
Molecular Formula:	$C_{90}H_{163}F_3N_{26}O_{24}S$
Molecular Weight:	2082.47
Sequence:	Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2
Sequence Shortening:	GMASKAGAIAGKIAKVALKAL-NH2
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BIOLOGICAL ACTIVITY

Description	PGLa TFA, a 21-residue peptide, is an antimicrobial peptide. PGLa TFA is a member of the magainin family of antibiotic peptides found in frog skin and its secretions[1].
IC_{50} & Target	Anti-bacteria[1]
In Vitro	PGLa is a peptide starting with a glycine and ending with a leucine amide[1]. PGLa is bacteriostatic against both Gram-positive and Gram-negative bacteria with MIC values of 64 and 32 mg/L against S. aureus and E. coli, respectively[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bechinger B, et al. Structure and dynamics of the antibiotic peptide PGLa in membranes by solution and solid-state nuclear magnetic resonance spectroscopy. Biophys J. 1998 Feb;74(2 Pt 1):981-7.

[2]. Radchenko DS, et al. Does a methionine-to-norleucine substitution in PGLa influence peptide-membrane interactions? Biochim Biophys Acta. 2016 Sep;1858(9):2019-27.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA